Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa
Open Access
- 15 August 2008
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 198 (4) , 544-552
- https://doi.org/10.1086/590185
Abstract
Background. The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune respKeywords
This publication has 46 references indexed in Scilit:
- Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy TrialsPLOS ONE, 2007
- Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populationsEuropean Journal of Immunology, 2007
- Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cellsNature Immunology, 2007
- Phenotypic and functional features of human Th17 cellsThe Journal of Experimental Medicine, 2007
- Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorNature Medicine, 2007
- The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette–Guérin vaccination in southern England and northern MalawiClinical and Experimental Immunology, 2006
- Extensively drug resistant tuberculosisBMJ, 2006
- Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cellsNature, 2006
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJournal of Clinical Investigation, 1999